Corresponding Author: Elyse R. Park, PhD, MPH, Health Policy Research Center, Mongan Institute, Massachusetts Hospital and Harvard Medical School, 100 Cambridge St, Ste 1600, Boston, MA 02114 (epark@mgh.harvard.edu).
Accepted for Publication: July 21, 2020.
Author Contributions: Dr Park had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Park, Muzikansky, Temel, Rigotti, Irwin, Hyland, Gonzalez, Whitlock, Malloy, de León-Sanchez, O’Brien, Ostroff.
Acquisition, analysis, or interpretation of data: Park, Perez, Regan, Muzikansky, Levy, Temel, Rigotti, Pirl, Irwin, Partridge, Cooley, Friedman, Rabin, Ponzani, Hyland, Holland, Borderud, Sprunck, Kwon, Peterson, Miller-Sobel, O’Brien, Ostroff.
Drafting of the manuscript: Park, Perez, Muzikansky, Temel, Friedman, Rabin, Ponzani, Borderud, Peterson, Miller-Sobel, Whitlock, Malloy, de León-Sanchez, O’Brien, Ostroff.
Critical revision of the manuscript for important intellectual content: Park, Perez, Regan, Muzikansky, Levy, Temel, Rigotti, Pirl, Irwin, Partridge, Cooley, Hyland, Holland, Sprunck, Kwon, Gonzalez, Whitlock, Ostroff.
Statistical analysis: Park, Regan, Muzikansky, Friedman, Rabin, O’Brien.
Obtained funding: Park, O’Brien, Ostroff.
Administrative, technical, or material support: Pirl, Cooley, Friedman, Rabin, Ponzani, Hyland, Borderud, Sprunck, Kwon, Peterson, Miller-Sobel, Gonzalez, Whitlock, Malloy, O’Brien, Ostroff.
Supervision: Park, Perez, Rigotti, Partridge, Borderud, Gonzalez, Whitlock, O’Brien, Ostroff.
Conflict of Interest Disclosures: Dr Park reported receiving a grant from Pfizer to support provision of varenicline for this study as well as grants from Pfizer outside the submitted work and royalties provided for a chapter, “Behavioral approaches for smoking cessation,” from UpToDate. Dr Levy reported receiving grants from the National Institutes of Health during the conduct of the study. Dr Temel reported receiving grants from Pfizer outside the submitted work. Dr Rigotti reported receiving grants from the National Cancer Institute during the conduct of the study and personal fees from UpToDate and Achieve Life Sciences outside the submitted work; and reported that Pfizer paid travel expenses but no personal fees for attendance at advisory committee meetings. Dr Pirl reported receiving financial support from Wiley for editorial services. Dr Irwin reported receiving grants from the National Institutes of Health/National Cancer Institute during the conduct of the study. Dr Cooley reported receiving grants from the National Cancer Institute during the conduct of the study. Dr Ostroff reported receiving royalties from UpToDate, an in-kind donation of nicotine replacement therapy from the CVS Foundation, and personal fees from ACS outside the submitted work. No other disclosures were reported.
Funding/Support: This research study was funded by the National Cancer Institute (grants 5 R01 CA166147-05 and 1 K24 CA197382) and Pfizer (grant Investigator-Initiated Research WS581690).
Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Data Sharing Statement: See Supplement 3.
Additional Contributions: We thank study consultants Robert Schnoll, PhD, University of Pennsylvania, Adam Goldstein, MD, MPH, University of North Carolina School of Medicine, Mary Ellen Wewers, PhD, MPH, The Ohio State University College of Public Health, and Carolyn Dresler, MD, MPA, Action on Smoking and Health. Drs Schnoll, Goldstein, and Wewers received compensation for their consultation on this study. We thank data and safety monitoring board members Donna Greenberg, MD (chair), Michael Lanuti, MD, Amy Comander, MD, Jonathan Winickoff, MD, MPH, and Hui Zheng, PhD. Dr Lanuti received compensation for his role on the data and safety monitoring board for this study. We express our gratitude for the oncology clinic liaisons at Massachusetts General Hospital: Jennifer Temel, MD, Michael Lanuti, MD, Beverly Moy, MD, Lori Wirth, MD, Philip Saylor, MD, Dave Ryan, MD, Donald Lawrence, MD, Jeremy Abramson, MD, and Richard Penson, MD. They did not receive compensation for their support of this study.
1.National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and Health.
The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General. Centers for Disease Control and Prevention; 2014. Accessed March 17, 2020.
https://www.ncbi.nlm.nih.gov/books/NBK179276/ 2.National Center for Chronic Disease Prevention and Health Promotion Office on Smoking and Health. Smoking Cessation: A Report of the Surgeon General. Centers for Disease Control and Prevention; 2020.
4.Westmaas
JL , Alcaraz
KI , Berg
CJ , Stein
KD . Prevalence and correlates of smoking and cessation-related behavior among survivors of ten cancers: findings from a nationwide survey nine years after diagnosis.
Cancer Epidemiol Biomarkers Prev. 2014;23(9):1783-1792. doi:
10.1158/1055-9965.EPI-14-0046
PubMedGoogle ScholarCrossref 5.Guimond
A-J , Croteau
VA , Savard
M-H , Bernard
P , Ivers
H , Savard
J . Predictors of smoking cessation and relapse in cancer patients and effect on psychological variables: an 18-month observational study.
Ann Behav Med. 2017;51(1):117-127. doi:
10.1007/s12160-016-9834-4
PubMedGoogle ScholarCrossref 6.Bluethmann
SM , Basen-Engquist
K , Vernon
SW ,
et al. Grasping the ‘teachable moment’: time since diagnosis, symptom burden and health behaviors in breast, colorectal and prostate cancer survivors.
Psychooncology. 2015;24(10):1250-1257. doi:
10.1002/pon.3857
PubMedGoogle ScholarCrossref 7.Goldstein
AO , Ripley-Moffitt
CE , Pathman
DE , Patsakham
KM . Tobacco use treatment at the US National Cancer Institute’s designated cancer centers.
Nicotine Tob Res. 2013;15(1):52-58. doi:
10.1093/ntr/nts083
PubMedGoogle ScholarCrossref 8.Ramaswamy
AT , Toll
BA , Chagpar
AB , Judson
BL . Smoking, cessation, and cessation counseling in patients with cancer: a population-based analysis.
Cancer. 2016;122(8):1247-1253. doi:
10.1002/cncr.29851
PubMedGoogle ScholarCrossref 9.Toll
BA , Brandon
TH , Gritz
ER , Warren
GW , Herbst
RS ; AACR Subcommittee on Tobacco and Cancer. Assessing tobacco use by cancer patients and facilitating cessation: an American Association for Cancer Research policy statement.
Clin Cancer Res. 2013;19(8):1941-1948. doi:
10.1158/1078-0432.CCR-13-0666
PubMedGoogle ScholarCrossref 12.Gritz
ER , Arnold
KB , Moinpour
CM ,
et al. Factors associated with adherence to an end-of-study biopsy: lessons from the prostate cancer prevention trial (SWOG-Coordinated Intergroup Study S9217).
Cancer Epidemiol Biomarkers Prev. 2014;23(8):1638-1648. doi:
10.1158/1055-9965.EPI-14-0202
PubMedGoogle ScholarCrossref 15.Glanz
K , Rimer
BK , Viswanath
K , eds. Health Behavior and Health Education: Theory, Research, and Practice. 4th ed. Jossey-Bass; 2008.
17.Fiore
MC , Jaén
CR , Baker
TB ,
et al. Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. US Department of Health and Human Services; 2008.
18.Piper
ME , Bullen
C , Krishnan-Sarin
S ,
et al. Defining and measuring abstinence in clinical trials of smoking cessation interventions: an updated review.
Nicotine Tob Res. 2020;22(7):1098-1106. doi:
10.1093/ntr/ntz110PubMedGoogle ScholarCrossref 19.Institute of Medicine Committee on Ethical and Legal Issues Relating to the Inclusion of Women in Clinical Studies. In: Mastroianni
AC , Faden
R , Federman
D , eds. NIH Revitalization Act of 1993 Public Law 103-43. National Academies Press; 1994.
34.Schafer
JL . Analysis of Incomplete Multivariate Data. 1st ed. Chapman & Hall/CRC; 1999.
35.Ostroff
JS , Burkhalter
JE , Cinciripini
PM ,
et al. Randomized trial of a presurgical scheduled reduced smoking intervention for patients newly diagnosed with cancer.
Health Psychol. 2014;33(7):737-747. doi:
10.1037/a0033186
PubMedGoogle ScholarCrossref 36.Schnoll
R , Leone
F , Veluz-Wilkins
A ,
et al. A randomized controlled trial of 24 weeks of varenicline for tobacco use among cancer patients: efficacy, safety, and adherence.
Psychooncology. 2019;28(3):561-569. doi:
10.1002/pon.4978
PubMedGoogle ScholarCrossref 37.Hall
SM , Humfleet
GL , Muñoz
RF , Reus
VI , Prochaska
JJ , Robbins
JA . Using extended cognitive behavioral treatment and medication to treat dependent smokers.
Am J Public Health. 2011;101(12):2349-2356. doi:
10.2105/AJPH.2010.300084
PubMedGoogle ScholarCrossref 40.Land
SR , Warren
GW , Crafts
JL ,
et al. Cognitive testing of tobacco use items for administration to patients with cancer and cancer survivors in clinical research.
Cancer. 2016;122(11):1728-1734. doi:
10.1002/cncr.29964
PubMedGoogle ScholarCrossref